Tagged with Manufacturing

France With demand for plasma-derived therapies rising steadily and Europe rethinking its biomanufacturing sovereignty, France’s LFB is quietly positioning itself for a leap onto the global stage. Backed by a EUR 750 million investment in a new industrial site and a unique public health mandate, the state-owned player is not just…

Brazil As Latin America’s largest pharma market, worth USD 62 billion in 2024, Brazil is retooling its industry to meet new demands. Driven by changing demographics, chronic disease burdens, and the growing expectations of a more affluent middle class, the Brazilian government is prioritising local production in key therapeutic niches while…

France Etienne Tichit has dedicated over five years to steering Novo Nordisk France through a transformative period of unprecedented growth and strategic realignment. His tenure has been marked by bold industrial investments exceeding EUR 2.3 billion, the establishment of France as a global manufacturing hub for next-generation diabetes and obesity treatments,…

Switzerland Marie Leblanc brings a distinctive combination of scientific rigor and commercial acumen to her role as Executive Vice President of Life Sciences at Biosynth, drawing from an 18-year tenure at Lonza where she witnessed the evolution of the contract development and manufacturing organisation (CDMO) industry from a traditional service provider…

France France is betting big on industrial transformation. With its sweeping EUR 54 billion France 2030 investment plan, the government has laid down a clear ambition: to become a global leader in innovation and industrial competitiveness. While foreign investment is flowing in, and biomedicine production is robust, local pharma industry leaders…

Denmark At first glance, Denmark might seem an unlikely hub for pharmaceutical production. With its small size and some of the highest labour costs in Europe, manufacturers might decide to look elsewhere. Yet major global players like Fujifilm Biotechnologies and AGC Biologics are doubling down on their Danish investments, expanding facilities…

Switzerland Pharmaceutical manufacturing is evolving into a strategic pillar of competitiveness, shaped by modular design, digital integration, and a growing focus on long-term efficiency. Bilfinger, through its Technology segment, is playing a central role in this transformation, supporting clients across biopharma, energy transition, and nuclear with scalable, future-ready solutions. In this…

Puerto Rico Spending almost 30 years working for a single company is almost unheard of in today’s life science industry, where executives chop and change between firms with bewildering frequency.   However, in CooperVision – one of the world’s leading soft contact lens manufacturers with Puerto Rico at its beating heart –…

Puerto Rico Can Puerto Rico capitalise on the Trump administration’s “make in America” push?   President Donald Trump wants to bring manufacturing back to America. The last 40 years of globalisation and free trade saw huge chunks of the US supply chain for all kinds of goods, including essential medicines and medical…

Puerto Rico Across over 50 interviews with Puerto Rican government and industry stakeholders, energy supply was continuously identified as the main barrier to growth. Puerto Rico’s ageing, centralised, and fossil fuel–dependent power system remains vulnerable to disruption from hurricanes and other natural events. However, new investments in renewables, battery storage, and decentralised…

Denmark Kasper Møller, Chief Technical Officer and General Manager of AGC Biologics Denmark, shares insights into the company’s strategic priorities and the role of its Copenhagen facility in AGC Biologics’ global network. Møller discusses the ongoing expansion of the site, the growing complexity of biologics manufacturing, and the evolving demands of…

France France is experiencing its biggest pharmaceutical manufacturing boom in decades, with global giants like Novo Nordisk, Sanofi, and Pfizer committing over EUR 4 billion in new investments since 2023. This wave of capital represents more than just expansion – it signals a broader pivot toward European pharmaceutical independence and potentially…